Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jan;39(1):504-517.
doi: 10.1007/s12325-021-01962-w. Epub 2021 Nov 18.

Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study

Affiliations
Observational Study

Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study

David Nanchen et al. Adv Ther. 2022 Jan.

Abstract

Introduction: The aims of this study were to describe patient characteristics, lipid parameters, lipid-lowering drug use, and safety of patients receiving evolocumab in a real-world clinical setting.

Methods: We conducted a 1-year multicenter observational study of adults using evolocumab with confirmed atherosclerotic cardiovascular disease (CVD) or at high cardiovascular risk, and elevated LDL-C despite maximally tolerated statin doses. An e-health application optionally supported patient management. The primary outcome was change in lipid parameters over time. The secondary outcomes included evolocumab safety.

Results: Of 100 participants, 81% had pre-existing CVD, 71% self-reported statin-related muscle symptoms, 44% received statins. All patients received evolocumab, 65% were PCSK9i pre-treated at baseline. PCSK9i-naïve patients achieved a mean LDL-C reduction of 60% within 3 months of evolocumab treatment, which was maintained thereafter; 74% achieved LDL-C < 1.8 mmol/L at least once during observation, 69% attained < 1.4 mmol/L. In PCSK9i pre-treated patients, LDL-C remained stable throughout; 79% and 74% attained < 1.8 mmol/L and < 1.4 mmol/L, respectively, at least once. Goal attainment was higher with any combination of evolocumab, statin, and/or ezetimibe. Overall, 89% self-reported full evolocumab adherence. Treatment-emergent adverse events (TEAE) were reported in 30% of patients, two serious TEAEs occurred in one patient; three patients discontinued evolocumab because of TEAEs.

Conclusion: In real-world clinical practice, evolocumab was mainly used in patients with statin intolerance and pre-existing CVD. In this population, adherence to evolocumab and low LDL-C levels were maintained over 1 year, with better LDL-C goal achievement in patients using evolocumab in combination with other lipid-lowering drugs. Safety of evolocumab was similar to that documented in randomized controlled trials.

Keywords: Adherence; Cardiovascular disease; Evolocumab; LDL-C goals; Real-world evidence; Reimbursement.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Lipid-lowering therapies and treatment outcomes in PCSK9 inhibitor-naïve and pre-treated patients. CI confidence interval, EAS European Atherosclerosis Society, ESC European Society of Cardiology, M month, LDL-C low-density lipoprotein cholesterol, PCSK9 proprotein convertase subtilisin/kexin type 9, PCSK9i PCSK9 inhibitor
Fig. 2
Fig. 2
Change in the number of patients receiving statin therapy over time, by statin intensity and PCSK9i status. Statin intensity, defined as per the American College of Cardiology/American Heart Association definition [28]

References

    1. Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381(16):1557–1567. doi: 10.1056/NEJMra1806939. - DOI - PubMed
    1. Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus. Circulation. 2018;137(15):1571–1582. doi: 10.1161/CIRCULATIONAHA.117.030950. - DOI - PubMed
    1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi: 10.1056/NEJMoa1615664. - DOI - PubMed
    1. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi: 10.1056/NEJMoa1801174. - DOI - PubMed
    1. Cholesterol Treatment Trialists’ Collaboration. Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi: 10.1016/S0140-6736(10)61350-5. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources